Nabota's sales in US in 1Q of the year were 92 billion won

A new record

Evolus announces results of 2Q

↑ 46% year-on-year

North American sales reached 92.2 billion won in the first half of the year, accumulated sales of 341 billion won

Daewoong Pharmaceutical's botulinum toxin drug Nabota broke a new quarterly sales record in North America.

 

Sales also improved in the second quarter following the first quarter, surpassing 90 billion won in sales in the first half.

 

Daewoong Pharmaceutical's partner Evolus announced on the 3rd (local time) that its sales of Jubo (Nabota) reached $37.16 million in the second quarter.

 

This is an increase of 46.3% compared to the same period last year.

 

This quarter's sales are the highest since Navota's launch in North America in the second quarter of 2019.

 

It surpassed 34.66 million dollars in the fourth quarter of last year, breaking a new quarterly sales record.

 

Nabota's sales in North America in the first half of the year increased 87% year-on-year to $70.39 million.

 

Since its launch, its cumulative sales have reached $260.2 million.

 

Evolus is a global copyrighted partner of botulinum toxin Nabota developed by Daewoong Pharmaceutical.

 

Since approval by the U.S.

 

Food and Drug Administration (FDA) in February 2019, Nabota has been actively sold in North America.

 

In particular, it resolved the negative factors by ending the International Trade Commission (ITC) dispute with Allergan and Medy Tox early last year.

 

It has become possible to actively market Jubo without legal concerns.

 

Navota's quarterly sales, which stood at $20 million last year, exceeded $30 million for the first time in the fourth quarter of last year.

 

Nabota added 590 new accounts in the second quarter, securing more than 8,100 customers so far.

 

The percentage of re-orders remains above 70%.

 

In the first half of this year, about 180,000 Evolus Reward loyalty programs were used.

 

Evolus is conducting more aggressive marketing.

 

Following the creation of more than 250 million media exposures in the second quarter, it also launched the largest promotional campaign under the name of "Switch Your Tox and Love Evolus Forever" last month.